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Background: Superior temporal cortices include brain regions dedicated to auditory processing and several lines
of evidence suggest structural and functional abnormalities in both schizophrenia and bipolar disorder within
this brain region. However, possible glutamatergic dysfunction within this region has not been investigated in
adult patients.
Methods: Thirty patientswith schizophrenia (38.67±12.46 years of age), 28 euthymic patientswith bipolar I dis-
order (35.32 ± 9.12 years of age), and 30 age-, gender- and education-matched healthy controls were enrolled.
Protonmagnetic resonance spectroscopy datawere acquiredusing a 3.0 T SiemensMAGNETOMTIMTrioMR sys-
tem and single voxel Point REsolved Spectroscopy Sequence (PRESS) in order to quantify brainmetabolites with-
in the left and right Heschl's gyrus and planum temporale of superior temporal cortices.
Results: There were significant abnormalities in glutamate (Glu) (F(2,78) = 8.52, p b 0.0001), N-acetyl aspartate
(tNAA) (F(2,81)=5.73, p=0.005), creatine (tCr) (F(2,83)=5.91, p=0.004) and inositol (Ins) (F(2,82)=8.49,
p b 0.0001) concentrations in the left superior temporal cortex. In general,metabolite levelswere lower for bipo-
lar disorder patients when compared to healthy participants. Moreover, patients with bipolar disorder exhibited
significantly lower tCr and Ins concentrations when compared to schizophrenia patients. In addition, we have
found significant correlations between the superior temporal cortex metabolites and clinical measures.
Conclusion: As the left auditory cortices are associatedwith language and speech, left hemisphere specific abnor-
malities may have clinical significance. Our findings are suggestive of shared glutamatergic abnormalities in
schizophrenia and bipolar disorder.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Emil Kraepelin's dichotomous approach to discriminate schizophre-
nia and bipolar disorder relies on their different clinical courses. Howev-
er, there has been discrepancy between Kraepelin's approach and
studies showing co-aggregation of schizophrenia and bipolar disorderAltindag, Ulus, Ankara, Turkey.
5 18.in families as well as shared susceptibility genes (Bramon and Sham,
2001; Craddock and Owen, 2005). The challenge arises due to the pres-
ence of overlapping symptoms between schizophrenia and bipolar dis-
order, but yet the desire for clear diagnostic categorization. Dimensional
concepts suggest focusing on symptom domains rather than diagnostic
categories (Cuthbert, 2014; Keshavan and Ongur, 2014). These symp-
tom domains in conjunction with biological findings may provide in-
sight for shared and distinct mechanisms underlying the disorders.
Superior temporal cortices host primary, secondary and association
auditory cortices and have been implicated in the pathophysiology of
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shown reductions in volume, thickness and gray matter content of the
superior temporal cortex in schizophrenia (Vita et al., 2012; Modinos
et al., 2013). Longitudinal studies report progressive gray matter loss
in the superior temporal gyrus and more precisely the Heschl's gyrus
and planum temporale with progression to psychosis and development
of delusions (Vita et al., 2012). Moreover, left superior temporal cortices
have been associated with symptom domains such as auditory halluci-
nations (Dierks et al., 1999; Jardri et al., 2011; Kuhn and Gallinat,
2012; Modinos et al., 2013; Shinn et al., 2013) and thought disorder
(Seese et al., 2011; Shenton et al., 1992) in psychosis. These findings
suggest the superior temporal gyrus as a highly relevant location for
the neurobiology and development of psychosis (Shenton et al., 1992;
Rajarethinam et al., 2000; Takahashi et al., 2006; Seese et al., 2011).
On the other hand, twometa-analyses of volumetric studies of superior
temporal cortices did not report any significant differences between pa-
tients with bipolar disorder and healthy participants (Kempton et al.,
2008; Arnone et al., 2009). However, primary and secondary auditory
cortices are located in the region and functional studies consistently re-
ported auditory processing disturbances in both schizophrenia (Dierks
et al., 1999; Umbricht and Krljes, 2005; Domjan et al., 2012) and bipolar
disorder (Hall et al., 2009; Oribe et al., 2010).
Since glutamate is the major excitatory neurotransmitter and since
the EEG signal consists of excitatory end synaptic potentials, auditory
processing deficits detected in both schizophrenia (Umbricht and
Krljes, 2005; Oribe et al., 2010) and bipolar disorder (Hall et al., 2009;
Ethridge et al., 2012; Atagun et al., 2014) could potentially be due to
glutamatergic dysfunction in the auditory cortices (Javitt, 2009).
Glutamate-modulating agents have been found to be efficacious in the
treatment of mood disorders both in pre-clinical (Skolnick et al.,
2009) and clinical studies (Sanacora et al., 2008; Machado-Vieira et al.,
2012). Current psychotomimetics also modulate different components
of the glutamatergic system (for reviews: (Machado-Vieira et al.,
2012; Sanacora et al., 2008)). Chronic treatment with lamotrigine,
valproate or lithium is likely to effect glutamatergic system through a
variety of mechanisms (for reviews: (Colla et al., 2009; Gigante et al.,
2012; Schifitto et al., 2009; Soeiro-de-Souza et al., 2013; Yatham et al.,
2009)). Therefore, the nature and extent of the glutamatergic system
abnormalities in patients with schizophrenia and mood disorders re-
quire further clarification.
Protonmagnetic resonance spectroscopy (1HMRS) is a non-invasive
neuroimaging technique that can quantify in vivo neurochemical
metabolites, including those related to the glutamatergic system. Gluta-
matergic neurotransmission is thought to be disturbed in both schizo-
phrenia (Goff and Coyle, 2001; Paz et al., 2008; Javitt, 2009, 2010) and
bipolar disorder (Sanacora et al., 2008; Machado-Vieira et al., 2012).
Moreover, altered glutamatergic metabolites have been reported both
in schizophrenia (Brugger et al., 2011; Marsman et al., 2013; Poels
et al., 2014a,b) and bipolar disorder (Yildiz-Yesiloglu and Ankerst,
2006; Moore et al., 2007; Yuksel and Ongur, 2010; Ongur et al., 2011).
Frontal, anterior cingulate and hippocampal regions are the most fre-
quently studied brain regions and the findings were consistent across
these brain regions. Only one study has investigated brain metabolites
within the superior temporal gyrus (Seese et al., 2011) and reported a
correlation between N-acetyl aspartate (NAA) concentrations and
thought disorder in children with schizophrenia. However, to our
knowledge, no single 1H MRS study has investigated the superior tem-
poral region and compared the findings in adult patients with schizo-
phrenia and patients with bipolar disorder.
Hence, in this study, we utilized 1H MRS to examine neuro-
metabolic changes within superior temporal cortices of adults with
schizophrenia or bipolar disorder. Studies by different research mo-
dalities consistently report structural and functional abnormalities
of auditory cortices, thus we expected to see abnormalities within
the neurochemical profile of this region in schizophrenia and/or bi-
polar disorder.2. Methods
2.1. Participants and study procedures
Thirty-five stable patients with paranoid schizophrenia (male or fe-
male; between ages of 18–59 years old) and 37 euthymic patients with
bipolar disorder (male or female; between ages of 20–54 years old)
were recruited for the study from the outpatient unit of Ankara Ataturk
Training and EducationHospital, Ankara, Turkey. Five of the schizophre-
nia and 3 of the bipolar patients could not attend the MRI session and
hence were excluded. Moreover, 5 of the bipolar patients had bipolar
disorder II and therefore were not included in the analysis and we
could not acquire neuroimaging data from 1 of the bipolar patients
due to technical issues. In addition, 30 age-, gender-, and education-
matched healthy participants (male or female; between ages of 18–58
years old) were enrolled in the study. All participants provided written
consent upon receiving detailed information about the study. The Ethi-
cal Committee of Yıldırım Beyazıt University approved the study.
All participants underwent a clinical interview administered by a
psychiatrist (MIA) and diagnoses were checked with the Structured
Clinical Interview according to the DSM-IV (SCID-I) (First et al., 1996).
The clinical interview assessed the participants' demographics and
medical/psychiatric history. Patients with bipolar disorder were evalu-
ated using the Young Mania Rating Scale (YMRS) (Young et al., 1978)
and the Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960).
Schizophrenia patients were evaluated with Scale for the Assessment
of Positive Symptoms (SAPS) (including subscores for delusion and hal-
lucination) (Andreasen, 1984) and Scale for the Assessment of Negative
Symptoms (SANS) (Andreasen, 1983). All patients were also evaluated
with the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham,
1962) and the Edinburgh Handedness Inventory (EHI) (Oldfield,
1971). All participants were free of any brain damage/surgeries or met-
abolic systemic diseases such as diabetes mellitus or hypertension or
current or lifetime psychiatric comorbidity or substance abuse. Psycho-
tropic medications except for benzodiazepines were allowed. Exclusion
criteria also included any contraindications to MRI scan. In addition
deafness or heading aids were excluded to avoid any possible plasticity
effects as a result of hearing disabilities, aswe are particularly interested
in the temporal lobe. Finally, all participants completed anMRI scanning
session.
2.2. NeuroImaging data acquisition
Datawere acquired on a 3.0 T SiemensMAGNETOMTIMTriowhole-
body MR system (Siemens, Erlangen, Germany) with a thirty two-
channel phased-array head coil at the UMRAMNational Magnetic Reso-
nance Research Center, Ankara, Turkey.
T1-weighted anatomical MRI (MPRAGE sequence, 256 × 256 voxels,
TR: 2000 ms, TE: 3.02 ms, FOV read: 215, FOV phase: 100, slice thick-
ness: 0.84, 192 slices)were collected for diagnostic and localization pur-
poses. Voxels (20mm× 20mm× 20mm)were placed consecutively in
the left and right Heschl's gyrus and planum temporale regions (Fig. 1)
and proton magnetic resonance spectroscopy (1H MRS) data were ac-
quired using the single voxel Point REsolved Spectroscopy Sequence
(PRESS) (TE= 30ms, TR=2000ms, 128 averages) in order to quantify
brain metabolites (Fig. 1). Manually adjusted B0 shimming was applied
around the voxel as implemented on our MR system.
2.3. NeuroImaging data analysis
The proton spectrawere fit using LCModel (Version 6.3.0) to quantify
the metabolite concentrations. LCModel analyzes in vivo proton spectra
as a linear combination of model in vitro spectra from individual metab-
olite solutions (Provencher, 1993, 2001) by utilizing built-in (simulated)
radial basis sets. The basis set used for this study included alanine, aspar-
tate, creatine (Cr), phosphocreatine (PCr), γ-aminobutyric acid (GABA),
Fig. 1. Representative proton spectrum and LCModel fit (red) with sample placement of
voxels (yellow) in the left and right superior temporal gyri.
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(GPC), phosphocholine (PCh), glutathione (GSH), inositol (Ins), lactate,
N-acetyl aspartate (NAA), N-acetyl aspartyl glutamate (NAAG), scyllo-
inositol, taurine as well as macromolecules and lipids. Total NAA
(tNAA, NAA and NAAG), Glu, Glx (Glu and Gln), total creatine (tCr, Cr
and PCr), total choline (tCh, GPC and PCh), and Ins were quantified and
fits with Cramer–Rao lower bounds (CRLB, estimated error of themetab-
olite quantification) of greater than 10% were classified as not reliably
detected and excluded from further analysis.
The structural T1-weighted imageswere segmented using SPM8 (Sta-
tistical ParameterMapping—WelcomeDepartment of ImagingNeurosci-
ence, London, UK; (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/)) to
determine the gray matter, white matter and CSF contributions to the
voxel of interest.
2.4. Statistics
Statistical analysis was performed using SPSS 21 (Armonk, NY: IBM
Corp.). First, we conducted an outlier analysis for eachmetabolite with-
in each group of participants. The values that were two standard devia-
tions away from the mean of their corresponding groups were
eliminated from further analysis. The remaining data were subjected
to univariate ANOVA to compare the findings across 3 groups, i.e.
schizophrenia patients vs. patients with bipolar disorder vs. healthy
participants; and metabolite levels were the dependent factors for
each comparison. Since we have 6 different metabolites (i.e. tNAA,
Glu, Glx, tCr, tCho and Ins), to account for the multiple comparisons
we considered p b 0.008 to be significant. We also performed post-hoc
analyses with Bonferonni corrections and for this part of the analysis
we considered p b 0.05 to be significant. In addition, we conducted an
ANCOVA to investigate the potential covariates that have clinical impor-
tance and cover a range of values within each group (i.e. age of onset
and duration of disorder as well asmedication effects). Further, we con-
ducted a Pearson's correlation analysis to explore the relationship be-
tween the brain metabolites and the clinical measures and for these
analyses we considered p b 0.05 to be significant.
3. Results
3.1. Participant demographics
Thirty remitted patients with paranoid schizophrenia (18 male; av-
erage age: 38.7±12.5 years) and28 euthymic patientswith bipolar dis-
order (13 male; average age: 35.3 ± 9.1 years) and 30 healthy
participants (13 male; average age: 32.8 ± 10.7 years) were included
in the study. There were no significant differences in any of the demo-
graphic variables across the groups (p N 0.05). Age of onset variedbetween the ages of 10 and 38 years for schizophrenia patients (average
age of onset: 22.5±6.4 years), and ages of 12 and 48 years (average age
of onset: 23.6 ± 8.7 years) for patients with bipolar disorder. Schizo-
phrenia patients scored significantly higher than patients with bipolar
disorder in BPRS (F(1,56) = 29.45, p b 0.0001). The demographic and
clinical characteristics of the sample are listed in Table 1.
In the schizophrenia group, there were three medication-free pa-
tients, 26 patients were on various mono-therapy antipsychotic medi-
cations and only 1 patient was taking both antipsychotic and
valproate together. In the bipolar disorder group, there were five
medication-free patients; the rest were on medication (valproate
mono-therapy (n = 3), combination therapy of valproate and antipsy-
chotics (n = 3), lithium monotherapy (n = 6), combination therapy
of lithium and antipsychotics (n=3), combination of valproate, lithium
and antipsychotics (n = 1), antipsychotic mono-therapy (n = 7)).
3.2. Brain metabolites
We evaluated the brain metabolites from the left and right Heschl's
gyrus and planum temporale regions separately. Statistically significant
findings are summarized in Table 2.
Within the left hemisphere voxel, Glu (F(2,78) = 8.52, p b 0.0001)
(Fig. 2A), tNAA (F(2,81) = 5.73, p = 0.005) (Fig. 2C), tCr (F(2,83) =
5.91, p = 0.004) (Fig. 2E) and Ins (F(2,82) = 8.49, p b 0.0001)
(Fig. 2G) levels were statistically significantly different among the
three groups. Post-hoc analysis revealed that tNAA, tCr and Ins levels
were similar between schizophrenia patients and healthy participants
(p N 0.1), but Glu levels were lower for schizophrenia patients than
that of healthy comparisons at a trend level (p = 0.1). For Glu, tNAA,
tCr and Ins, patients with bipolar disorder exhibited lower levels when
compared to healthy participants (Glu: p b 0.0001; tNAA: p = 0.004;
tCr: p = 0.008; Ins: p = 0.003). In addition, tCr and Ins levels were
higher for patients with schizophrenia when compared to patients
with bipolar disorder (tCr: p = 0.016; Ins: p = 0.001). Due to the
wide ranges in age at onset, duration of illness, and medication status,
we further investigated the differences in Glu, tNAA, tCr and Ins
among patients with bipolar disorder and schizophrenia patients by ac-
counting for age onset, duration of disorder and the chlorpromazine
equivalent values of medicated patients; results are summarized in
Table 2.
On the other hand, there were no statistically significant metabolite
differences within the right hemisphere voxel (Glu: Fig. 2B; tNAA:
Fig. 2D; tCr: Fig. 2F; Ins: Fig. 2H).
Since there was no statistically significant differences between
groups in terms of voxel tissue content (left hemisphere: gray matter
— (F(2,84) = 0.73, p = 0.48), white matter — (F(2,84) = 0.22, p =
0.81), csf — F(2,84) = 0.78, p = 0.46; right hemisphere: gray matter
— (F(2,84) = 0.25, p = 0.78), white matter — (F(2,84) = 0.75, p =
0.47), csf — F(2,84) = 1.98, p = 0.15) we did not factor gray matter/
white matter/csf amounts into our analysis.
3.3. Association between brain metabolites and clinical measures
For schizophrenia patients, we performed exploratory correlation
analyses to investigate the relationship between the brain metabolites
and SAPS (total scores and subscores for bizarre behavior, formal
thought disorder, inappropriate affect, delusion, and hallucination)
and SANS (total scores and subscores for avolition, affective flattening,
anhedonia, alogia, and attention).
Glu showed relationships with SANS affective flattening (r = 0.44,
p = 0.02) and attention (r = 0.44, p = 0.02) subscores, only for the
right hemisphere. tNAA exhibited inverse relationships with SANS
alogia (r = −0.44, p = 0.02) and attention subscores (r = −0.44,
p = 0.02) in the left hemisphere. tCr had inverse correlations with
SAPS total score (r = −0.37, p = 0.05), SAPS delusion subscore (r =
−0.46, p = 0.01), SANS anhedonia (r=−0.46, p = 0.01), SANS alogia
Table 1
Clinical characteristics of participants.
Schizophrenia (n = 30) Bipolar disorder (n = 28) Healthy controls (n = 30) F/X2/t p
Age 38. 7 ± 12.5 35.3 ± 9.1 32.8 ± 10.7 2.22 0.115
Gender (F) 12 15 17 1.88 0.391
Education 9.30 ± 3.2 10.89 ± 4.9 10.20 ± 3.4 1.24 0.294
Age at onset of disorder (years) 22.5 ± 6.4 23.6 ± 8.7 0.89 0.578
Duration of disorder (months) 147.5 ± 132.1 92.2 ± 107.7 3.19 0.089
Number of previous hospitalizations 2.4 ± 5.1 1.4 ± 1.8 2.12 0.328
Number of previous episodes Total 7.8 ± 5.4
Manic 2.8 ± 2.2
Depressive 4.2 ± 3.4
Chlorpromazine equivalent (mg) 259.90 ± 228.54 144.4 ± 231.83 0.005 0.061
Serum lithium levels (mEq/l) (n = 9) 0.67 ± 0.22
Serum valproate levels (μg/ml) (n = 10) 73.53 ± 27.08
BPRS 7.67 ± 4.29 2.43 ± 2.86 3.20 b0.001
YMRS 1.07 ± 1.61
HDRS 3.46 ± 3.51
SAPS Total 11.0 ± 6.66
Bizarre behavior 1.16 ± 1.52
Formal thought disorder 0.47 ± 1.01
Inappropriate affect 1.23 ± 0.73
Delusions 5.10 ± 3.79
Hallucination 2.60 ± 3.84
SANS Total 14.13 ± 8.56
Avolition 2.77 ± 2.83
Affective flattening 4.13 ± 2.49
Anhedonia 2.87 ± 1.83
Alogia 2.03 ± 2.27
Attention 2.33 ± 1.86
Averages are reportedwith standard deviations. One-way ANOVA, Chi-Square test and t test. BPRS: Brief Psychiatric Rating Scale, HDRS:Hamilton Depression Rating Scale, SANS: Schedule
for the Assessment of Negative Symptoms, SAPS: Schedule for the Assessment of Positive Symptoms, YMRS: Young Mania Rating Scale.
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tionships with SAPS delusion subscore (r=−0.42 p= 0.03), SANS an-
hedonia (r=−0.47, p= 0.01), and SANS alogia (r=−0.39, p= 0.04)
in the left hemisphere.
For patients with bipolar disorder, we performed exploratory corre-
lation analyses to investigate the relationship between the brainmetab-
olites and YMRS, HDRS and BPRS. tNAA showed inverse relationships
with HDRS for left (r = −0.46, p = 0.02) and right hemispheres (r =
−0.41, p = 0.03). tCr also exhibited inverse correlation with HDRS for
left (r = −0.39, p = 0.05) and right (r = −0.44, p = 0.02) hemi-
spheres. In addition, Ins and HDRS had a reverse relationship in the
right hemisphere (r = −0.52, p = 0.005).Table 2
1H MRS findings.
Schizophrenia (n = 30) Bipolar
Left hemisphere
Glu 0.00088 ± 0.00011 0.0008
Covariates: (related to disorder) Age onset
Duration
CPZE
tNAA 0.00111 ± 0.00016 0.0010
Covariates: (related to disorder) Age onset
Duration
CPZE
tCr 0.00080 ± 0.00011 0.0007
Covariates: (related to disorder) Age onset
Duration
CPZE
Ins 0.00067 ± 0.00010 0.0005
Covariates: (related to disorder) Age onset
Duration
CPZE
Absolute quantity averages are reported with standard deviations. Univariate ANOVA. CPZE: ch4. Discussion
In this study, we observed decreased Glu concentrations within the
left Heschl's gyrus and planum temporale of the superior temporal
gyrus of patients with schizophrenia and bipolar disorder when com-
pared to healthy participants. On the other hand, Glu, tNAA, tCr and
Ins concentrations of the bipolar disorder groupwere lower when com-
pared to schizophrenia patients and healthy participants. Moreover, tCr
and Ins concentrations in the left superior temporal gyrus of schizo-
phrenia patientswere significantly higher than the concentrationsmea-
sured from patients with bipolar disorder. All of these differences in
metabolite levels between groups reached statistical significance only
in the left superior temporal cortex, suggesting a possible location-disorder (n = 28) Healthy controls (n = 30) F p
2 ± 0.00010 0.00095 ± 0.00013 F(2,78) = 8.52 b0.0001
F(1,50) = 4.39 0.041
F(1,50) = 4.64 0.036
F(1,36) = 5.78 0.021
4 ± 0.00015 0.00117 ± 0.00013 F(2,81) = 5.73 0.005
F(1,52) = 3.53 0.066
F(1,52) = 3.73 0.059
F(1,36) = 2.83 0.101
1 ± 0.00011 0.00080 ± 0.00011 F(2,83) = 5.91 0.004
F(1,52) = 8.91 0.004
F(1,52) = 7.26 0.009
F(1,36) = 6.40 0.016
7 ± 0.00012 0.00067 ± 0.00011 F(2,82) = 8.49 b0.0001
F(1,52) = 14.48 b0.0001
F(1,52) = 11.25 0.001
F(1,35) = 6.64 0.014
lorpromazine equivalent.
Fig. 2. Absolute metabolite concentrations for patients with schizophrenia (SCH), bipolar disorder (BD), and healthy control participants (HC) acquired from the superior temporal gyrus
using 1H MRS. Glutamate (Glu) from (A) left and (b) right superior temporal gyri; Total N-acetyl aspartate (tNAA) from (C) left and (D) right superior temporal gyri; total creatine (tCr)
from (E) left and (F) right superior temporal gyri; inositol (Ins) from (G) left and (H) right superior temporal gyri. * denotes statistically significant difference between groups (p b 0.008).
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ces for schizophrenia and bipolar disorder patients. It has been shown
that auditory cortices are functionally lateralized (Zatorre et al., 1992;
Kell et al., 2011) and the auditory cortex of the dominant hemisphereis associated with psychiatric disorders (Dierks et al., 1999; Plaze
et al., 2006; Shinn et al., 2013).
Previous studies have reported glutamatergic abnormalities related
to clinical progression in schizophrenia observed within different
207M.İ. Atagün et al. / Schizophrenia Research 161 (2015) 202–209brain regions such as the anterior cingulate cortex (Goff and Coyle,
2001; Clinton and Meador-Woodruff, 2004; Kugaya and Sanacora,
2005; Javitt et al., 2012). Specifically, schizophrenia patients have
exhibited increased concentrations of glutamatergic metabolites if the
patients were in a first-episode and conversely, decreased concentra-
tions if the patients had a chronic disease (Ohrmann et al., 2005;
Ohrmann et al., 2008; Marsman et al., 2013; Schwerk et al., 2014). A re-
cent study, investigating schizophrenia patients showed elevated Gln
and Gln-to-Glu ratio but no significant difference in Glu levels in pa-
tients when compared to healthy comparisons (Bustillo et al., 2014).
Our findings in a cohort of chronic schizophrenia patients exhibited de-
creased Glu concentrations at trend level for schizophrenia patients
when compared to healthy participants and no change for Glx concen-
trations were observed.
Previous reports did not find any difference in Glu concentrations
between patients with bipolar disorder and healthy participants
(Gigante et al., 2012); however they consistently showed increase in
Glx concentration for bipolar disorder patients, regardless of mood
state (Yuksel and Ongur, 2010; Gigante et al., 2012). Although alter-
ations in Glx have been suggested tomostly reflect changes in Glu levels
(Dager et al., 2004), previous reports are suggestive of abnormalities in
other components of the composite Glx peak, such as Gln (Moore et al.,
2007), rather than Glu. However, our findings showed significant differ-
ence in Glu levels but not in Glx concentrations.
Glutamate turnover may be altered in different ways, resulting in
changes in Gln-to-Glu ratio, depending on the disease state, i.e. manic
(Ongur et al., 2008) or depressive (Auer et al., 2000) phases of bipolar
disorder (reviewed in (Yuksel and Ongur, 2010)). These findings sug-
gest an alteration in glutamatergic dysfunction between mania and de-
pression for bipolar disorder. Glial cells are responsible for Glu–Gln
cycling (Tansey et al., 1991; Cooper et al., 2003); therefore glial abnor-
malities are potentially the basis of differences between mania and de-
pression in bipolar disorder (Ongur et al., 1998). Unfortunately, thefield
strength of theMRI scanner used in the current study did not allowus to
reliably quantify Gln concentrations. We can only speculate that since
the Glx levels did not differ between groups, but Glu concentrations
were lower for both schizophrenia and bipolar disorder patients when
compared to healthy participants, Gln levels may have been elevated.
Taken together, it is possible to suggest that abnormalities in the Gln/
Glu cycle might be a cause of the observed reduction in Glu levels for
the patients with bipolar disorder.
NAA is known to be lower in schizophrenia and bipolar disorder pa-
tients (Steen et al., 2005; Yildiz-Yesiloglu and Ankerst, 2006; Kraguljac
et al., 2012a,b). Our investigation did not reveal any significant abnor-
mality in tNAA concentrations in schizophrenia patients, possibly due
to medication effects (Szulc et al., 2011; Kraguljac et al., 2012a; Szulc
et al., 2013), but exhibited reduced tNAA levels for bipolar patients.
tCr and Ins levels remain unchanged in schizophrenia (Schwerk et al.,
2014) and our findings confirm this statement. However, there are a
few studies that found reduced tCr levels in dorsolateral prefrontal
cortex, anterior cingulate cortex, hippocampus and basal ganglia of
schizophrenia patients (Ohrmann et al., 2005; Ohrmann et al., 2007;
Ongur et al., 2009). In addition, the literature is not conclusive about
the concentrations of Cr and Ins for patients with bipolar disorder
(Yildiz-Yesiloglu and Ankerst, 2006; Frey et al., 2007; Theberge et al.,
2007; Ongur et al., 2009; Silverstone and McGrath, 2009; Kraguljac
et al., 2012a; Sikoglu et al., 2013). The decrease in tNAA, tCr and Ins
that we observed in patients with bipolar disorder compared to healthy
participants may be a region specific disturbance in this disorder, as we
investigated an understudied brain area, i.e. the left superior temporal
cortex. Regardless, these abnormalities are suggestive of abnormalities
in neurochemicals other than glutamate in bipolar disorder.
The comparison of findings frompatientswith schizophrenia and bi-
polar disorder revealed significant differences only for tCr and Ins levels.
The auditory system may show different abnormalities at multiple
levels both in schizophrenia and bipolar disorder (Skold et al., 2014).Our observationsmay imply that there exist common, i.e. glutamatergic
dysfunction, as well as distinct abnormalities, i.e. in brain bioenergetics
in schizophrenia and bipolar disorder within the auditory system.
Previous studies have focused primarily on higher order cortices,
such as the frontal lobe where different channels of information con-
verge and hence conduct serial and parallel processing together. How-
ever, lower order sensory areas, such as the auditory cortices have
simpler receptive fields with only serial processing capabilities
(Yamada and Wilber, 1990; Rauschecker and Scott, 2009; Homan
et al., 2014). Given the fact that the pathophysiology of psychiatric dis-
orders is so complicated and these disorders may have different influ-
ences on different neural systems and circuits, investigating the
primary sensory areas may provide an advantage. Therefore, in this
study we focused on the superior temporal gyrus to acquire 1H MRS
data.
Previous studies in the left STG in schizophrenia revealed correla-
tions with clinical data, which suggests a relationship between the re-
gion and the effects of clinical factors. A 31P MRS study reported
correlation between the hallucination score of the Positive and Negative
Syndrome Scale (PANSS) and phosphomonoesters and phosphodiesters
(Nenadic et al., 2014). A recent 1H MRS study comparing hallucinations
in the STG reported that NAA/Cr ratio correlatedwith total and negative
subscore of the PANSS in schizophrenia (Homan et al., 2014). Neuronal
activation patterns for patients with auditory hallucinations were more
prominent for the left hemispherewhen compared to non-hallucinating
patients as shown by functional neuroimaging studies with auditory
tasks (Dierks et al., 1999; Shinn et al., 2013),whichmay indicate the rel-
evance of the left auditory cortex. Besides, the auditory processing def-
icits in functional studies (Hall et al., 2009; Oribe et al., 2010; Domjan
et al., 2012; Atagun et al., 2013; Atagun et al., 2014) point to abnormal-
ities of the auditory cortices both in schizophrenia and bipolar disorder.
In this study, both schizophrenia and bipolar disorder patients exhibited
relationships between the studied metabolites and some of the clinical
measures, especially on the left hemisphere. For example, HDRS scores
correlated tCr and Ins concentrations in superior temporal cortices.
This is particularly important as it may indicate a relationship between
the metabolite levels and mood status.
5. Limitations
The current study had several limitations. First, our patients were
patients with chronic disease and all were medicated. Although there
was no statistically significant medication effect, small numbers of pa-
tients were taking each individual medication; therefore we cannot ex-
cludemedication effects conclusively. It is still possible that some of the
metabolites were altered due to medications. Second, at 3 T magnetic
field strength, some of the metabolite peaks in the 1H-MRS spectrum
cannot be decomposed. In spite of the high quality of the glutamate out-
put, it is difficult to completely discriminate glutamate from glutamine
and GABA signal amplitudes, thus we could only identify Glu and Glx
levels. Third, 8 cm3 voxel volumes cover an area larger than the auditory
cortices alone.
6. Conclusion
Overlapping symptoms and intermediate diagnoses suggest that
schizophrenia and bipolar disorder are disorders on a continuum.
Genome wide association studies have identified shared risk genes in
schizophrenia and bipolar disorder involving glutamatergicmetabolism
and cascades (see review; Coyle, 2006), which are in line with the
glutamatergic abnormalities we have observed. Given that neurotrans-
mission and intracellular functions are two major functions of gluta-
matergic metabolites, future studies focusing on glutamatergic
abnormalities may provide novel targets for treatment development
for both schizophrenia and bipolar disorder. In addition, this study re-
ports a significant difference between creatine and inositol levels in
208 M.İ. Atagün et al. / Schizophrenia Research 161 (2015) 202–209patients with schizophrenia and bipolar disorder in the left superior
temporal region. Taken together, there may be both shared and distinct
mechanistic abnormalities within auditory cortices underlying patho-
physiologies of schizophrenia and bipolar disorder. Therefore, our find-
ingsmay suggest biological markers thatmay quantitatively distinguish
the two disorders, and might be of importance for future studies.
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